Filing Flows › Biocryst Pharmaceuticals (BCRX) › Q1 2025
Biocryst Pharmaceuticals (BCRX) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 6, 2025
Biocryst Pharmaceuticals (BCRX) reported revenue of $146M for the first quarter 2025 (Q1 2025), +57% from a year earlier and +11% from the quarter before. Operating margin was 14.6%, net earnings $32K (0.0% of revenue).
Biocryst Pharmaceuticals, Q1 2025: revenue $146M (+57% year over year), operating margin 14.6%, net earnings $32K, operating cash flow −$27.5M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $146M | +11% | +57% |
| Operating profit | $21.2M | — | — |
| Net earnings | $32K | — | — |
| Operating cash flow | −$27.5M | — | — |
What changed
Revenue was $145.5M in Q1 2025, up 57% year over year and up 11% from the previous quarter. ORLADEYO was the largest line at 92% of revenue. ORLADEYO added $45.4M year over year (up 51%), 86% of the total change.
Operating profit was $21.2M, a 14.6% margin (up 30.2 points year over year). Total costs grew 16% against revenue growth of 57%. The fastest-growing cost line was Cost of revenue (+261%). Net earnings were $32K. The effective tax rate was 95.8%.
Operating cash flow was −$27.5M. Non-cash charges added back $331K of depreciation and amortization and $21.4M of share-based compensation. Working capital and other items used $49.2M. Capital expenditures of $143K exceeded it, leaving free cash flow of −$27.7M.
Questions
What was Biocryst Pharmaceuticals' revenue in the first quarter 2025?
Biocryst Pharmaceuticals (BCRX) reported revenue of $146M for the first quarter 2025 (Q1 2025), +57% from a year earlier and +11% from the quarter before.
Was Biocryst Pharmaceuticals profitable in the first quarter 2025?
Operating profit was $21.2M (14.6% of revenue) and net earnings $32K.